Press Releases
TTi's Slogan
- 2025/10/7
Tripartite Therapeutics to present at World ADC San Diego 2025
We are excited to present our OmniLink universal linker technology at the World ADC San Diego 2025! Come listen to Dr. Young-Sun Lin, our Chief Scientific Officer, present a scientific poster with preclinical results highlighting application of our technologies to different antibodies on Nov 4, 2025. We would also like to extend a warm welcome for everyone to visit us at booth 34 to explore how our technologies can help create better ADCs for tomorrow! - 2025/9/30
Tripartite Therapeutics Shortlisted for TPEx 2025 GISA Plus Elite Award
Tripartite Therapeutics is proud to announce that we competed against over 100 companies for innovation, creativity and future development potential, and have been selected as one of the companies shortlisted for the Taipei Exchange (TPEx) 2025 GISA Plus Elite Award!
Read the full Taipei Exchange announcement here:
https://www.tpex.org.tw/en-us/about/company/press/detail.html?lang=en-us&id=12386
Full list of shortlisted companies:
https://brandstudio.tnlmedia.com/2025/GISA_EliteAward/announce.htm - 2017/1/5
Tripartite Therapeutics to Present at The Biotech Showcase™ 2017 Conference on January 11th, 2017
Taipei, Taiwan --- Tripartite Therapeutics, Inc. announced that it will be featured as a presenting company at The Biotech Showcase™ 2017 Conference taking place from January 9-11, 2017 in San Francisco, California.
President and Chief Scientific Officer, Young-sun Lin, PhD, is scheduled to present on Wednesday, January 11, 2017 at 10:45 AM PST. Mr. Anthony Lin, Chairman of the Board, will be available to participate in meetings with the investment community during the conference.
If you are an investor and wish to attend the Company's presentation or schedule a meeting at the conference, please click on the following link: http://www.ebdgroup.com/bts/registration/index.php.
About The Biotech Showcase™ 2017 Conference
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.
Source: Tripartite Therapeutics, Inc.
Released January 5, 2017